Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Reverse Split to uplist NASDAQ?
AMDX Amarantus Diagnostic Division Call Letters
Eltoprazine dosage timing
https://twitter.com/g_commish/status/585990080679903232
Print
Congressman Fattah Meets with Biotech Company on Brain Research Efforts; Announced as Co-Chair of Alzheimer's Caucus
02/03/15
WASHINGTON – Congressman Chaka Fattah (D-PA), architect of the Fattah Neuroscience Initiative, met last week with Amarantus, a biotechnology company on their recent efforts to develop treatment and diagnostics for degenerative brain diseases, including Alzheimer’s.
At the meeting, Amarantus CEO Gerald Commissiong and CFO Robert Farrell briefed Congressman Fattah on a new agreement between the company and Georgetown University for six patent rights related to blood based biomarkers for Alzheimer’s disease; the rights are currently jointly owned by Georgetown and the University of Rochester. Amarantus said that these biomarkers will be crucial in identifying at-risk individuals for Alzheimer’s and the ability to test therapeutic agents that could delay or prevent the disease.
“I continue to be impressed by the advanced research happening within the neuroscience field. This new agreement is an important milestone in Alzheimer’s diagnostic development with the potential to help recognize individuals who may be at-risk for Alzheimer’s and ultimately develop the information necessary to better detect and diagnose the disease,” Congressman Fattah said. “Through the Fattah Neuroscience Initiative, I look forward to continuing to work with public and private entities to ensure our country is focused on the research and development that will lead to breakthroughs in the field.”
The briefing also highlighted the importance of genomic testing for Alzheimer’s disease and the growing need for increased federal commitment to Alzheimer’s research and funding. Alzheimer’s disease is the third leading cause of death in the United States. Currently more than 5.4 million individuals are suffering from the disease—a number that is expected to increase as Americans continue to lengthen their lifespan.
Fattah, who has led Congress in efforts to increase public funding for brain research was also named as one of four co-chairs of the House Alzheimer’s Disease Caucus last week.
In a release he said, “It is a privilege to join as a caucus co-chair and work within Congress to advocate for policies, research, and funding that will advance our efforts to fight Alzheimer’s disease. Degenerative diseases are a toppriority in the neuroscience field and the need for action on Alzheimer’s grows by the day as the United States and nations around the world confront its crippling social and economic effects. I thank my fellow co-chairs for their longstanding efforts, and look forward to making more progress on this issue in the 114th Congress.”
The Caucus appointment comes days after Fattah was announced to serve on the Appropriations Subcommittee on Labor, Health and Human Services, Education and related agencies—the body responsible for funding the National Institutes of Health. Fattah additionally serves as the lead Democrat on the Commerce, Justice, and Science (CJS) Subcommittee which funds the National Science Foundation. Through both these roles, Fattah hopes to continue pressing for heightened attention to neuroscience.
Created three years ago, the Fattah Neuroscience Initiative has sought to prioritize neuroscience in the United States, increase public-private partnerships around brain research, and expand research collaboration between countries across the globe. The Initiative is credited with forming the Interagency Working Group on Neuroscience (IWGN) housed at the White House, which was an impetus for the BRAIN Initiative. Congressman Fattah has worked with public and private organizations throughout the country in order to promote neuroscience as a federal priority and initiate groundbreaking partnerships in neuroscience research.
###
Dirk's tweet: Benitec cancer collaborator switches to synthetic RNAi triggers and PLK1 target:
http://www.ncbi.nlm.nih.gov/pubmed/25557168
Oncotarget. 2014 Dec 20. [Epub ahead of print]
Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.
McCarroll JA1, Dwarte T2, Baigude H3, Dang J4, Yang L2, Erlich RB1, Kimpton K2, Teo J1, Sagnella SM1, Akerfeldt MC2, Liu J5, Phillips PA6, Rana TM4, Kavallaris M1.
Author information
Abstract
Non-small cell lung cancer (NSCLC) remains the most common cause of cancer death worldwide due its resistance to chemotherapy and aggressive tumor growth. Polo-like kinase 1 (PLK1) is a serine-threonine protein kinase which is overexpressed in cancer cells, and plays a major role in regulating tumor growth. A number of PLK1 inhibitors are in clinical trial; however, poor tumor bioavailability and off-target effects limit their efficacy. Short-interfering-RNA (siRNA) holds promise as a class of therapeutics, which can selectively silence disease-causing genes. However, siRNA cannot enter cells without a delivery vehicle. Herein, we investigated whether RNAi-interfering nanoparticles could deliver siRNA to NSCLC cells and silence PLK1 expression in vitro and in vivo. iNOP-7 was non-toxic, and delivered siRNA with high efficiency to NSCLC cells. iNOP-7-PLK1 siRNA silenced PLK1 expression and reduced NSCLC growth in vitro. Notably, iNOP-7 delivered siRNA to orthotopic lung tumors in mice, and administration of iNOP-7-PLK1 siRNA reduced lung tumor burden. These novel data show that iNOP-7 can deliver siRNA against PLK1 to NSCLC cells, and decrease cell proliferation both in vitro and in vivo. iNOP-7-PLK1 siRNA may provide a novel therapeutic strategy for the treatment of NSCLC as well as other cancers which aberrantly express this gene.
Benitec cancer collaborator switches to synthetic RNAi triggers and PLK1 target: http://t.co/EAJLRRBpqF
— Dirk Haussecker (@RNAiAnalyst) January 27, 2015
I was in a Scottrade office and he was reading it to me, maybe it was just Scottrade phasing it out but I remember 2016-2017
as the date.
From Benitec's web site:
"For some time there has been an unsponsored ADR program in the U.S. with Benitec shares trading as BNIKF. Benitec has no control over this unsponsored ADR program.
The unsponsored ADR program will remain in place, however shareholders of BNIKF will be able to transfer to the new sponsored ADR (BTEBY). Holders of BNIKF ADRs may transfer their holding to the new sponsored ADRs (BTEBY) without attracting an issuance fee by BNY Mellon for transactions before July 31, 2014.
BNIKF has an expiration date I believe.
Try financial engineering and LYMPRO spinoff correlation
$30 Million per year - "As a result of MANF being designated as an Orphan Drug, Amarantus is now entitled to certain R&D tax credits equivalent to 50% of the qualified clinical testing expenses for development, a waiver of PDUFA fees, access to government grants and contracts totalling $30 million per year, and seven years of market exclusivity post approval for the target indication."
Evidently his arch nemesis:
. @BiotechWill Um... Joe Rubenfield is the kiss of death. He leaves a wake of destruction. Huge red flag for $AMBS.
— Adam Feuerstein ✡️ (@adamfeuerstein) December 8, 2014
WRONG AGAIN! Provide quote where article says "will not work for PD" if you can, but you CAN NOT!
WRONG AGAIN! Extrapolation is out of orbit. Quote from article: "Nigral MANF overexpression had no effect on amphetamine-induced rotations or TH striatal fibre density but resulted in a significant preservation of TH(+) cells" IS NOT EQUIVALENT to your quote: "this says that MANF by itself will not work for PD"
TOTALLY WRONG!
Jason Napodano "The company is also developing an AD diagnostic test with early results showing sensitivity (correctly diagnosing AD) = 97% and specificity (correctly identifying individuals without AD) = 96%."
http://seekingalpha.com/article/2575735-neurotrope-tackles-alzheimers-disease-with-novel-mechanism
Got few questions this morning: Sensitivity is the likelihood we identify true AD / Specificity is the likelihood we identify true non-AD
— Gerald Commissiong (@G_Commish) October 9, 2014
Good point
Probably not imo
MANF / AMBS Renishaw collaboration with UCSF coming imo
WRONG! Eltoprazine start possibilities mentioned BEFORE conference!!!
BOGUS! The issue is your statement "implies that they do not have any grants for this yet, nor have they applied for them" obviously ignores the fact that grant writing info has been previously disclosed. Your post is BOGUS. Your inference is BOGUS. Your DD is BOGUS. CONCEDE!
WRONG! "implies that they do not have any grants for this yet, nor have they applied for them" Grant writing info previously disclosed - You are WRONG once again
WRONG! "by 2015" denotes occurrence either in 2014 or 2015
Give the quote and time reference or REMOVE your post.
When I have quoted from CC in past, I have included time
and direct quote. Give the direct quote and time reference or REMOVE your subjective, false post.
Give the quote and time reference or REMOVE your post.
Show the complaint or remove your post.
http://www.thestreet.com/story/12876014/1/ebola-stricken-doc-receives-experimental-drug-but-which-one.html?puc=yahoo&cm_ven=YAHOO
".@apwriter Am now 99% certain Dr Sacra is successfully receiving Tekmira TKM-EBOV ebola therapy. 1% just because nothing is certain $TKMR — egomaniakos (@egomaniakos) September 11, 2014"
5 of the 6 patients in the first cohort have been dosed:
"Our collaborator UCSF is working with the NIH to conduct a Phase I clinical trial of a gene therapy for Parkinson’s disease consisting of an AAV2-based vector carrying the GDNF gene we have exclusively licensed, produced in a third party mammalian cell-based manufacturing process. This trial is sponsored and funded by the NIH. The aim of this clinical trial is to introduce the GDNF gene to provide a consistent supply of GDNF to the relevant areas of the brain. In this clinical trial, the NIH is using convection enhanced delivery with the goal of achieving more precisely targeted administration than the methods used in early approaches, which may result in improved efficacy."
I see a high probability of MANF following the same roadmap
as Uni***e
DNA directed RNA interference - gene therapy
P16 platform could be ddRNAi with the Benitec/Ross connection now.
Qualitative: relating to, measuring, or measured by the quality of something rather than its quantity.
They would have to move to a level 2 ADR first, correct?
Aug 15: Vol 19.1 K. Short Vol 9 K
Short Vol Ratio: 0.471